The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global extracorporeal membrane oxygenation machine market exhibited moderate growth during 2015-2020. Extracorporeal membrane oxygenation (ECMO) machine refers to a miniaturized heart-lung equipment used for supporting respiratory and cardiac functions during transplant surgeries. ECMO drains the blood and removes carbon dioxide from the patient’s body to artificially oxygenate the red blood cells. It is also used in late-stage treatments or post-cardiopulmonary bypass with heart or lung failure. ECMO is commonly available in two variants, namely, Veno-Venous (VV) and Veno-Arterial (VA). VV involves attaching cannulas to large veins in the body to drain the blood and remove the carbon dioxide, thereby providing support only to the lungs. Whereas, VA ECMO is used for supporting the functioning of both heart and lungs by draining and pumping the blood throughout the body.
The increasing prevalence of respiratory and cardiovascular disorders across the globe is one of the key factors driving the growth of the market. ECMO is used for both adults, newborns and children suffering from respiratory or cardiac failure due to congenital disabilities, trauma or severe infections. Furthermore, the rising geriatric population, which is more susceptible to chronic medical ailments, is providing a thrust to the market growth. In line with this, increasing patient awareness regarding the benefits of timely ECMO procedures is also contributing to the growth of the market. Various technological advancements, such as the development of polymethyl pentene (PMP) fiber-based artificial membranes with low-resistance and improved biocompatibility, are acting as other growth-inducing factors. Equipment manufacturers are also developing compact ECMO machines for enhanced portability and convenient oxygenation of the blood. Other factors, including rising healthcare expenditure capacities of the masses, along with extensive research and development (R&D) activities, are anticipated to drive the market toward growth. Looking forward, IMARC Group expects the global extracorporeal membrane oxygenation machine market to grow at a CAGR of around 5% during the forecast period (2021-2026).
IMARC Group provides an analysis of the key trends in each sub-segment of the global extracorporeal membrane oxygenation machine market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, component, modality, patient type and application.
Breakup by Component:
Breakup by Modality:
Breakup by Patient Type:
Breakup by Application:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, ALung Technologies Inc., Braile Biomedical, Eurosets, LivaNova PLC, Medtronic, MicroPort Scientific Corporation, Nipro Medical Corporation, Origen Biomedical, Inc., Terumo Corporation and Xenios AG.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at